Topics

Startup stories Company stories Markets & events People & wealth Family offices

AI & automation

Business automation Industry AI Agents & tools Physical AI

Funding & fundraising Startups & growth Business & growth Acquisitions & ownership

People

All people Investors Angel investors Wealth Founders Boards Executives Leadership changes Get your profile

New Wealth

Explore New Wealth After a business sale Navigating an inheritance Employee equity payouts Large investment gains

Connections Startups Companies Investors Directory Library Get Featured

WatchlistSign in

Home
Companies
ImmunoBiochem

I

Company profile

ImmunoBiochem

ImmunoBiochem develops antibody-directed therapeutic candidates for immunology and inflammation.

Follow ImmunoBiochemFollowingFollow ImmunoBiochem

Website All coverage

My watchlist RSS feed

Overview

ImmunoBiochem develops degrader-antibody conjugates for immunology and inflammation. Its lead autoimmune candidate, IMB216P, is designed to combine an antibody target with a protein-degrading payload.

The company has also developed oncology antibodies. In 2023 it announced an agreement licensing antibodies against an undisclosed target to ImmunoGen, with further payments contingent on specified milestones.

Legal company name: ImmunoBiochem Corporation

Loading profile details…

Industries

Industry category: Healthcare & Life Sciences
Specific industry: Drug Discovery

Classification sources and history

Drug Discovery · Business involvement
As of 2026-11-09

Loading recent changes…

Sources & editorial review

(2)

ImmunoBiochem platform and pipeline
ImmunoBiochem oncology licence announcement

Editorial profile by MoneyMakers. Sources reviewed 10 November 2026.

About Branding Family Offices Articles Stock movers Opportunities List a Business Business Ideas Validate Founders to Watch Get Featured Pricing Business Terms T&C Privacy Refunds Contact

All publications RSS News RSS Guides RSS

Home
Companies
ImmunoBiochem

Follow ImmunoBiochemFollowingFollow ImmunoBiochem

Website All coverage

My watchlist RSS feed

Latest reporting

Conceptual illustration for ImmunoBiochem of a blue antibody-like molecule linked by a purple sphere to a receptor on a cell surface, with a larger purple spiky sphere nearby.

Startups & growth Analysis

ImmunoBiochem is developing antibody-directed protein degraders for autoimmune disease

ImmunoBiochem is developing an autoimmune drug candidate that pairs an antibody with a protein-degrading payload. An earlier oncology licence shows one potential route to commercialization.

ImmunoBiochem | Antibody-Directed Therapeutics - MoneyMakers

Brand marks identify the organization. Logo from the official website.

People at the company

AN

Anton Neschadim

Founder

Founder of ImmunoBiochem.

View personal profile